grant
PET and MRI Evaluation of Cerebral Inflammation and Metabolic Stress in Relapsing Multiple Sclerosis
Organization WASHINGTON UNIVERSITYLocation SAINT LOUIS, UNITED STATESPosted 15 Jul 2023Deadline 30 Jun 2028
NIHUS FederalResearch GrantFY202518-FDG18F- FDG18FDG2 Fluoro 2 deoxy D glucose2-Fluoro-2-deoxyglucoseAffectAgeAnti-CD20 AntibodyAtrophicAtrophyAutoregulationAxonB blood cellsB cellB cell depletion therapyB cell directed therapyB cell targeted therapyB cell therapiesB cell therapyB cellsB-CellsB-LymphocytesB-cellBBB crossingBindingBiological MarkersBody TissuesBrain InflammationCNS Degenerative DiseasesCNS Degenerative DisordersCareer Development AwardsCareer Development Awards and ProgramsCareer Development Programs K-SeriesCell BodyCell Communication and SignalingCell DeathCell SignalingCellsCentral Nervous System Degenerative DiseasesCerebrumClinicalClinical assessmentsD-GlucoseDataDemyelinating DiseasesDemyelinating DisordersDemyelinationsDextroseDisability statusDiseaseDisease remissionDisorderDisseminated SclerosisDrug ModulationDrugsDysfunctionEdg ReceptorsEncephalitisEquilibriumEvaluationFDA approvedFailureFunctional disorderGlucoseGlycolysisHomeostasisImageImmuneImmunesImmunochemical ImmunologicImmunologicImmunologicalImmunologicallyImmunologicsInflammationInflammatoryInflammatory ResponseInjuryIntermediary MetabolismIntracellular Communication and SignalingK-AwardsK-Series Research Career ProgramsKnowledgeLesionMR ImagingMR TomographyMRIMRIsMS LesionsMS patientMS treatmentMagnetic Resonance ImagingMeasurementMeasuresMediatingMedicalMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMedicationMentorsMetabolicMetabolic ProcessesMetabolic stressMetabolismMiceMice MammalsModelingMolecular InteractionMonitorMorbidityMorbidity - disease rateMultiple SclerosisMultiple Sclerosis LesionsMurineMusMyelinNMR ImagingNMR TomographyNatureNerve DegenerationNeurological disabilityNeuron DegenerationNuclear Magnetic Resonance ImagingO elementO2 elementOutcomeOxygenPETPET ScanPET imagingPETSCANPETTParticipantPathologyPatientsPersonsPharmaceutical PreparationsPhysiological HomeostasisPhysiopathologyPositionPositioning AttributePositron Emission Tomography Medical ImagingPositron Emission Tomography ScanPositron-Emission TomographyProcessRad.-PETRefractoryRelapseRelapsing-Remitting Multiple SclerosisRemissionResearch Career ProgramS1P ReceptorScanningSignal TransductionSignal Transduction SystemsSignalingSphingosine-1-Phosphate ReceptorStressTestingTherapeuticTissuesZeugmatographyagesanti-CD20balancebalance functionbio-markersbiologic markerbiological signal transductionbiomarkerblood-brain barrier crossingbloodbrain barrier crossingbrain tissuecerebralchronic demyelinationcohortcompare to controlcomparison controlde-myelinating diseasesde-myelinating disordersdemyelinatedemyelinating conditionsdemyelination diseasesdemyelination disordersdisabilitydrug/agenteffective therapyeffective treatmentefficacious therapyefficacious treatmentfluorodeoxyglucoseglucose uptakegray matterimagingimaging agentinflammation markerinflammatory markerinjuriesinsular sclerosisinterestkinetic modellymphocyte traffickingmetabolic imagingmetabolic ratemultiple sclerosis patientmultiple sclerosis therapymultiple sclerosis treatmentnecrocytosisnerve injuryneural degenerationneural imagingneural injuryneuro-imagingneurodegenerationneurodegenerativeneuroimagingneurological degenerationneurological imagingneuronal degenerationnoveloverexpressoverexpressionpathophysiologypatients with MSpatients with multiple sclerosispeople with Multiple sclerosispositron emission tomographic (PET) imagingpositron emission tomographic imagingpositron emitting tomographyradiolabelradiolabelsradiotracerrecruitrepairrepairedresponsesubstantia albasubstantia griseatreatment effecttreatment strategyuptakewhite matter
Description preview
ABSTRACT
Multiple sclerosis (MS) is an immune-mediated, demyelinating, and degenerative disease of the central
nervous system and is a leading cause of disability in young people. Most patients begin with a relapsing-
remitting (RRMS) course. Clinical relapse and new white matter lesion formation is dramatically reduced by
current therapies.…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click